Drug-induced Torsades de Pointes is a rare, unpredictable, and life-threatening serious adverse event. It can be caused by both cardiac and non-cardiac drugs and has become a major issue in novel drug development and for the regulatory authorities. This review describes the problem, predisposing factors, and the underlying genetic predisposition as it is understood currently. The future potential for pharmacogenomic-guided and personalized prescription to prevent drug-induced Torsades de Pointes is discussed. Database searches utilized reports from www.qtdrugs.org up to January 2012, case reports and articles from www.pubmed.com up to January 2012, and the British National Formulary edition at www.bnf.org.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3538275 | PMC |
| http://dx.doi.org/10.1093/eurheartj/ehs351 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Safety Profile of Amiodarone Among Older Adults (age ≥ 75 years): A Pharmacovigilance Study from the FDA Data.
Am J Med
January 2025
The Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Sheba Medical Center, Ramat-Gan, Israel; Division of Geriatric Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Electronic address:
Background: Amiodarone is a widely used antiarrhythmic agent with significant toxicities and drug interactions more likely to affect older adults. Nevertheless, data regarding amiodarone safety in this population are limited.
Methods: We conducted a retrospective analysis of FDA Adverse Event Reporting System (FAERS) data from 2003 to 2024 .
Cardiotoxicity evaluation of two-drug fixed-dose combination therapy under CiPA: a computational study.
Transl Clin Pharmacol
December 2024
Computational Medicine Lab, Department of IT Convergence Engineering, Kumoh National Institute of Technology, Gumi 39177, Korea.
The Comprehensive Proarrhythmia Assay (CiPA) evaluates drug-induced torsade de pointes (TdP) risk, with qNet commonly used to classify drugs into low-, intermediate-, and high-risk categories. While most studies focus on single-drug effects, 2-drug fixed-dose combination (FDC) therapy is widely used for cardiovascular disease management. We aimed to develop the CiPA-based methodology to predict adverse effects of FDC therapy.
View Article and Find Full Text PDFInvestigating the effects of remdesivir on corrected QT interval in patients with severe COVID-19 disease: a historical cohort study.
BMC Cardiovasc Disord
December 2024
Department of Biostatics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.
Article Synopsis
- There is limited information on how remdesivir, an FDA-approved drug for COVID-19, affects QT prolongation, which can lead to serious heart issues.
- A historical cohort study involving 249 patients assessed QTc changes before and after five days of remdesivir treatment, alongside monitoring several health metrics.
- The findings indicated significant changes in other health parameters but found no substantial effect on QTc prolongation, suggesting remdesivir does not increase the QTc interval in severe COVID-19 patients.
Quantitative Structure-Activity Relationship Models to Predict Cardiac Adverse Effects.
Chem Res Toxicol
December 2024
FDA Center for Drug Evaluation and Research (CDER), Silver Spring, Maryland 20903, United States.
Article Synopsis
- Drug-induced cardiotoxicity is a major reason why drug candidates fail during development, making its evaluation critical in drug testing and regulatory review.
- The study analyzed FDA postmarket adverse events for 2002 drugs, categorizing cardiac toxicity-related terms into 12 relevant groups to create training sets for model development.
- Researchers used two commercial QSAR platforms to develop 12 predictive models, achieving up to 80% sensitivity and negative predictivity, which can improve the screening of potential cardiotoxic drugs in the development process.
Polygenic risk score for drug-induced long QT syndrome: independent validation in a real-world patient cohort.
Pharmacogenet Genomics
January 2025
Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan.
Article Synopsis
- Drug-induced long QT syndrome (diLQTS) is a serious side effect of over 150 medications that can lead to dangerous heart conditions; the study aimed to validate a genetic risk score for predicting this syndrome.
- Researchers analyzed data from a large cohort of patients taking high-risk QT-prolonging drugs and found that the risk score was significantly associated with diLQTS in White patients, indicating a higher likelihood of QT prolongation during treatment.
- Although the risk score showed promise in identifying high-risk individuals, the study was underpowered to confirm its effectiveness across African American and Asian populations, highlighting the need for larger sample sizes in diverse groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!